The deal, which expands Medtronic’s presence in the surgical technology market, involves payments of $480 million for Salient and $105 million for PEAK, not including Medtronic’s previous ownership stake.
Both PEAK and Salient will be under Medtronic’s restorative therapies group, which includes its spinal, neuromodulation, diabetes and surgical technology units.
Related Articles on Medtronic:
Surgical Equipment Business in Better Shape Than Radiology, Cardiology
Medtronic, St. Jude Developing Competing Neurostimulation Systems
Ford, Medtronic Partner on Glucose Monitoring Device for Cars
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
